As shown in Fig. 6g, h, enzalutamide slightly suppressed LuCaP 35CR tumor growth but did not reach significance (p = 0.54), APO significantly suppressed LuCaP 35CR growth (p = 0.026), while combination of APO and enzalutamide further reduced tumor growth (p = 0.0087). The gene discussed is AOPEP; the disease is neoplasm.